KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GoodRx Holdings (GDRX) Other Accumulated Expenses (2019 - 2023)

GoodRx Holdings' Other Accumulated Expenses history spans 5 years, with the latest figure at $8.5 million for Q1 2023.

  • On a quarterly basis, Other Accumulated Expenses rose 77.36% to $8.5 million in Q1 2023 year-over-year; TTM through Mar 2023 was $8.5 million, a 77.36% increase, with the full-year FY2022 number at $6.9 million, up 58.98% from a year prior.
  • Other Accumulated Expenses hit $8.5 million in Q1 2023 for GoodRx Holdings, up from $6.9 million in the prior quarter.
  • Over the last five years, Other Accumulated Expenses for GDRX hit a ceiling of $11.4 million in Q3 2022 and a floor of $1.9 million in Q4 2019.
  • Historically, Other Accumulated Expenses has averaged $5.9 million across 5 years, with a median of $5.2 million in 2021.
  • Biggest five-year swings in Other Accumulated Expenses: surged 278.91% in 2020 and later plummeted 39.64% in 2021.
  • Tracing GDRX's Other Accumulated Expenses over 5 years: stood at $1.9 million in 2019, then surged by 278.91% to $7.2 million in 2020, then plummeted by 39.64% to $4.3 million in 2021, then soared by 58.98% to $6.9 million in 2022, then rose by 23.44% to $8.5 million in 2023.
  • Business Quant data shows Other Accumulated Expenses for GDRX at $8.5 million in Q1 2023, $6.9 million in Q4 2022, and $11.4 million in Q3 2022.